Levodopa/carbidopa subcutaneous - NeuroDerm
Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680Latest Information Update: 06 Nov 2024
Price :
$50 *
At a glance
- Originator NeuroDerm
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Parkinson's disease
Most Recent Events
- 01 Nov 2024 NeuroDerm held a Type A meeting with the US FDA to discuss the contents of the CRL
- 01 Nov 2024 NeuroDerm plans to resubmit the NDA to US FDA for Parkinson’s Disease
- 11 Jun 2024 Mitsubishi Tanabe Pharma Corporation receives complete response letter from the FDA for levodopa/carbidopa in Parkinson’s disease